Prestige Consumer Healthcare Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2023 (FY2023), compared primarily with FY2022. Although the request metadata says “2022 Q4,” this filing reports the full fiscal year, not a standalone quarter. Prestige develops, markets and distributes over-the-counter health and personal-care products. Its reportable segments are North American OTC Healthcare and International OTC Healthcare.
Financial performance
| Metric | FY2023 | FY2022 | Change / context |
|---|---|---|---|
| Total revenue | $1,127.7 million | $1,086.8 million | Up 3.8% |
| Gross profit / margin | $625.3 million / 55.4% | $620.6 million / 57.1% | Profit up 0.7%; margin fell 1.7 percentage points, primarily from supply-chain costs and product mix |
| Operating income (loss) | $(22.4) million | $329.9 million | FY2023 included $370.2 million of goodwill and intangible-asset impairment charges |
| Net income (loss) | $(82.3) million | $205.4 million | FY2023 diluted loss per share was $1.65; FY2022 diluted EPS was $4.04 |
| Operating cash flow | $229.7 million | $259.9 million | Down $30.2 million, primarily due to increased working capital |
| Cash and cash equivalents | $58.5 million | $27.2 million | Increased $31.3 million over the year |
| Debt | $1,360.0 million principal | $1,495.0 million principal | Includes $400 million of 5.125% notes due 2028, $600 million of 3.750% notes due 2031 and $360 million term-loan borrowings |
| Interest expense, net | $69.2 million | $64.3 million | Average borrowing cost rose to 4.8% from 4.1% |
North American revenue rose 0.6% to $973.8 million; International revenue increased 29.4% to $154.0 million, with growth mainly in Australia, including Hydralyte. North American gross margin declined to 54.6% from 56.7%; International gross margin was broadly flat at 60.6%.
Material changes and unusual items
- The company recorded $370.2 million of impairment charges: $48.8 million for goodwill in North American Women’s Health and Oral Care, and $321.4 million for intangible assets, including Summer’s Eve, DenTek, TheraTears and certain non-core brands. The company attributed impairments mainly to higher discount rates and, for Summer’s Eve, lower long-term sales projections. These non-cash charges drove the reported operating and net losses.
- International revenue increased its share of total revenue to 13.7% from 10.9%. Within North America, Cough & Cold revenue rose 15.4%, while Women’s Health revenue declined 7.0%.
- Financing cash outflows included $135.0 million of term-loan repayments and $50.0 million of share repurchases. Investing cash use was $11.6 million, compared with $256.5 million in FY2022, which included $247.0 million for acquisitions.
- At year-end, the ABL revolver had no amount outstanding and $168.7 million of borrowing capacity. The company reported compliance with debt covenants.
Outlook, risks and contingencies
- Management said operating cash generation and existing credit facilities are expected to fund working capital and capital expenditures for the next 12 months, excluding acquisitions; this is not a quantified earnings or revenue forecast. The filing provides no specific numerical guidance.
- Management described economic conditions as volatile, citing inflation, rising interest rates, supply-chain constraints, labor availability and geopolitical uncertainty. Higher input and logistics costs have pressured gross margin; further price increases could also affect demand and market share.
- Prestige relies on third-party manufacturers and a single primary U.S. distribution center. It disclosed that Akorn’s U.S. parent filed for Chapter 7 liquidation; Akorn AG continued manufacturing TheraTears under a supply arrangement, but could cease operations. Prestige said it was seeking and qualifying alternative manufacturers.
- Walmart represented 19.7% of FY2023 gross revenue and approximately 20% of year-end receivables. The company also cited customer concentration, retailer inventory policies, private-label competition and limited long-term customer agreements as risks.
- Approximately $360 million of debt carried variable interest rates. Management noted rates were rising and expected to continue rising in FY2024; a one-percentage-point increase would have increased FY2023 pre-tax loss and cash outflows by approximately $4.6 million, holding other factors constant. The ABL reference rate was changed from LIBOR to SOFR on April 4, 2023.
- Routine legal claims were not expected by management to be material, taking recorded reserves into account. The auditor issued an unqualified opinion and reported effective internal control over financial reporting; impairment valuation was identified as a critical audit matter.
Important facts for investors to verify
- Whether sales and margins recover, particularly in North American Women’s Health, and whether International growth continues.
- The assumptions behind the $370.2 million impairment, including brand sales forecasts and discount rates; Monistat was identified as a sensitivity area.
- TheraTears inventory coverage and progress in qualifying replacement suppliers following Akorn’s Chapter 7 filing.
- Working-capital trends, debt service costs, variable-rate exposure and covenant headroom.
- Customer concentration, especially Walmart, and the effects of retailer inventory and pricing policies.